News Reports and Commentaries

/News Reports and Commentaries

Neuren’s Trofinetide Successful in Phase 2 Clinical Trial in Fragile X Syndrome

I was honored to have been invited to represent the Fragile X community and the NFXF at the recent meeting sponsored by Neuren Pharmaceuticals, in which they shared some very encouraging news regarding their Phase [...]

By | 2015-12-07T17:33:48+00:00 Dec 7, 2015|FXS, In the News, News Reports and Commentaries|Comments Off on Neuren’s Trofinetide Successful in Phase 2 Clinical Trial in Fragile X Syndrome

Summary Reports from 2015 Summer Student Fellowship Research Fund Studies

This summer, the NFXF funded four summer student research fellowships at $2500 each through the  Summer Student Fellowship Research Fund. Since its inception in 2000, the fund has awarded $225,000 to 90 students focused on [...]

By | 2015-09-30T14:57:15+00:00 Sep 30, 2015|News Reports and Commentaries, Summer Student Fellowship Reports|Comments Off on Summary Reports from 2015 Summer Student Fellowship Research Fund Studies

Neuroimmunology Meets Neurodevelopmental: Innate and Adaptive Immune Function in FXS

Neuroimmunology is a relatively new field at the intersection of neuroscience and immunology. Its purpose is to describe how immune function affects brain development and function, and how signaling between cells in the brain affect levels [...]

By | 2014-11-13T17:01:56+00:00 Nov 13, 2014|News Reports and Commentaries|Comments Off on Neuroimmunology Meets Neurodevelopmental: Innate and Adaptive Immune Function in FXS

The Future of Fragile X Public Health Research

A message from the Jeffrey Cohen, NFXF interim executive director. >> I recently attended a meeting focusing on "The Future of Fragile X Public Health Research.” One of the hot topics was how the collection of public health data can improve how we measure success in clinical trials results....

By | 2014-07-03T09:28:28+00:00 Jul 3, 2014|From the Executive Director, Keeping You Informed, News Reports and Commentaries|Comments Off on The Future of Fragile X Public Health Research

Novartis Announces Results of Mavoglurant (mGluR5) (AFQ056) Clinical Trials and the Conclusion of the Long-Term Extension Study

Earlier this month Novartis released results of the Phase IIb/III studies with mavoglurant (AFQ056) in adolescents with Fragile X syndrome (FXS). The trial results from the study of adults were released late last year. Both studies did not meet [...]

By | 2014-04-24T10:51:28+00:00 Apr 24, 2014|News Reports and Commentaries, Novartis AFQ056|Comments Off on Novartis Announces Results of Mavoglurant (mGluR5) (AFQ056) Clinical Trials and the Conclusion of the Long-Term Extension Study

Progressive Neurodegenerative Disorder (FXTAS) Linked to R-loop Formation, UC Davis Researchers Find

Researchers at UC Davis have identified a new feature of the genetic mutation responsible for the progressive neurodegenerative disorder Fragile X-associated tremor/ataxia syndrome (FXTAS) — the formation of “R-loops,” which they believe may be associated with the disorder’s neurological symptoms, such as tremors, lack of balance, features of Parkinsonism and cognitive decline.

By | 2014-04-18T14:18:42+00:00 Apr 18, 2014|News Reports and Commentaries|Comments Off on Progressive Neurodegenerative Disorder (FXTAS) Linked to R-loop Formation, UC Davis Researchers Find
Load More Posts